Immedica Acquires Marinus Pharmaceuticals for $151 Million
On December 30, Immedica Pharma announced that it acquired Marinus Pharmaceuticals, Inc. for approximately $151 million. Immedica will acquire all the outstanding shares of Marinus common stock for a cash purchase price of $0.55 per share, representing a premium of 48% based on Marinus’ closing share price as of December 27th and a premium of 97%, based on the 30-day volume-weighted average price of $0.28 per share preceding the announcement of the transaction. Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY® (ganaxolone) oral suspension CV, is an... Read More »
Celltrion Builds Out Foothold in Europe With iQone Healthcare Switzerland Acquisition
Celltrion announced its acquisition of iQone Healthcare Switzerland, strengthening its presence in Europe, driving growth and expanding access to its biosimilar treatments. iQone Healthcare Switzerland is an independent Swiss-based specialty pharmaceutical company dedicated to the commercialization of biosimilars and innovative treatments for rare diseases. Through its long-standing collaborations with several global pharmaceutical developers and manufacturers, iQone Healthcare provides a continually expanding selection of leading biosimilars and products to healthcare professionals and institutions in Switzerland. Celltrion is a leading biopharmaceutical company, specializing in the... Read More »
DRI Healthcare Trust Acquires Interest in KalVista Pharmaceuticals’ Sebetralstat for $100 Million
On November 4, DRI Healthcare Trust announced that it acquired the royalty interest in Sebetralstat, a novel investigational candidate for the oral, on-demand treatment of hereditary angioedema from KalVista Pharmaceuticals, Inc. Sebetralstat is under regulatory review by the FDA with a Prescription Drug User Fee Act goal date of June 17, 2025. KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. DRI Healthcare Trust is a healthcare royalty investment company based in Toronto. The company is managed by DRI Capital, a Canadian healthcare royalty private equity firm. Since its initial public offering in 2021, DRI has deployed more than $1 billion, acquiring more... Read More »
Lundbeck Acquires Longboard Pharmaceuticals for $2.6 Billion
H. Lundbeck A/S, a specialty pharmaceutical company, announced that it acquired Longboard Pharmaceuticals. Longboard shareholders will be offered a payment of $60 per share in cash. The transaction is valued at approximately $2.6 billion equity value and $2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis. The cash consideration represents a 77% premium to the 30-day volume-weighted average price of shares of Longboard common stock as of September 30, 2024. Longboard is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard’s small molecule product candidates are based... Read More »
Siemens Buys Novartis’s Nuclear Diagnostics Segment for $223 Million
Siemens Healthineers announced it acquired Advanced Accelerator Applications S.A. (AAA) for $223 million from Novartis AG. AAA, a radiopharmaceutical company, develops, produces and commercializes molecular nuclear medicines including Lutathera® (177Lu-DOTATATE), a first-in-class RLT product for neuroendocrine tumors. Radiopharmaceuticals are unique medicinal formulations containing radioisotopes which are used clinically for both diagnosis and therapy. Novartis bought AAA in 2017 for $3.9 billion. Siemens Healthineers manages a portfolio of products and services in areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
